FY2028 Earnings Forecast for ALDX Issued By Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Leerink Partnrs dropped their FY2028 earnings per share estimates for shares of Aldeyra Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of $2.50 per share for the year, down from their prior estimate of $2.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.48) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25).

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Stock Down 3.2 %

Shares of ALDX opened at $4.27 on Friday. The company has a 50-day moving average of $5.53 and a two-hundred day moving average of $4.60. Aldeyra Therapeutics has a one year low of $2.43 and a one year high of $6.55. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Aldeyra Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in shares of Aldeyra Therapeutics by 23.4% in the 1st quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 4,797 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Aldeyra Therapeutics by 106.3% in the 1st quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock worth $1,478,000 after acquiring an additional 233,169 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Aldeyra Therapeutics by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 3,446 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of Aldeyra Therapeutics by 3.3% in the first quarter. Kennedy Capital Management LLC now owns 1,318,155 shares of the biotechnology company’s stock valued at $4,310,000 after purchasing an additional 42,009 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Aldeyra Therapeutics in the first quarter worth $585,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.